Reference health
Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics
159/159 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
8 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 159 checked references that resolve
resolves10.1176/appi.ajp.159.6.1005
Trends in the Treatment of Bipolar Disorder by Outpatient Psychiatrists
resolves10.1016/j.jad.2009.01.024
Use of lithium in the adult populations of Denmark, Norway and Sweden
resolves10.1023/A:1010319610021
Lithium Revisited: Savings Brought About by the Use of Lithium, 1970–1991
resolves10.1176/appi.ajp.161.2.217
Long-Term Lithium Therapy for Bipolar Disorder: Systematic Review and Meta-Analysis of Randomized Controlled Trials
resolves10.1186/s40345-014-0015-8
Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis
resolves10.1136/bmj.f3646
Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
resolves10.4088/JCP.v68n0617
Acceleration and Augmentation of Antidepressants With Lithium for Depressive Disorders
resolves10.1111/bdi.12025
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
resolves10.1001/archpsyc.59.6.530
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
resolves10.1111/acps.12343
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis
resolves10.1016/S0140-6736(11)61516-X
Lithium toxicity profile: a systematic review and meta-analysis
resolves10.1016/j.pharmthera.2010.07.006
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders
resolves10.1111/acps.12139
Lithium's role in neural plasticity and its implications for mood disorders
resolves10.1038/sj.mp.4001306
Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks
resolves10.1192/bjp.bp.113.129916
The 25th anniversary of the launch of Prozac gives pause for thought: where did we go wrong?
resolves10.1034/j.1399-5618.2001.030203.x
The prophylactic effect of long‐term lithium administration in bipolar patients entering treatment in the 1970s and 1980s
resolves10.1371/journal.pone.0065636
Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report
resolves10.1192/bjp.bp.112.113548
Treatment in a specialised out-patient mood disorder clinic
<i>v.</i>
standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial
resolves10.1055/s-2000-7965
Mortality in 497 Patients with Affective Disorders Attending a Lithium Clinic or after Having Left it
resolves10.1192/S0007125000292453
Length of Lithium Treatment Needed to Eliminate the High Mortality of Affective Disorders
resolves10.1073/pnas.95.14.8363
Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex
resolves10.1016/S0006-3223(00)00929-X
Signaling: cellular insights into the pathophysiology of bipolar disorder
resolves10.1192/bjp.bp.112.110858
Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value
resolves10.1016/j.biopsych.2012.06.015
Brain Structural Signature of Familial Predisposition for Bipolar Disorder: Replicable Evidence For Involvement of the Right Inferior Frontal Gyrus
resolves10.1016/0022-3956(73)90005-8
Intracellular lithium concentration and clinical response: Towards a membrane theory of depression
resolves10.1016/0165-1781(82)90007-5
The red blood cell/plasma lithium ratio: Marker of biological heterogeneity within bipolar affective illness?
resolves10.1016/0091-3057(76)90030-7
Lithium levels in monkey and human brain after chronic, therapeutic, oral dosage
resolves10.1001/archpsyc.61.3.300
Molecular Evidence for Mitochondrial Dysfunction in Bipolar Disorder
resolves10.1001/archpsyc.64.5.555
Differences in Lymphocyte Electron Transport Gene Expression Levels Between Subjects With Bipolar Disorder and Normal Controls in Response to Glucose Deprivation Stress
resolves10.1001/archgenpsychiatry.2010.22
Mitochondrial Complex I Activity and Oxidative Damage to Mitochondrial Proteins in the Prefrontal Cortex of Patients With Bipolar Disorder
resolves10.1111/j.1365-2796.2006.01745.x
New roles for an old enzyme: Na,K‐ATPase emerges as an interesting drug target
resolves10.1111/j.1472-8206.2008.00620.x
Na<sup>+</sup>/K<sup>+</sup>‐ATPase‐mediated signal transduction and Na<sup>+</sup>/K<sup>+</sup>‐ATPase regulation
resolves10.1073/pnas.1108416108
Mania-like behavior induced by genetic dysfunction of the neuron-specific Na
<sup>+</sup>
,K
<sup>+</sup>
-ATPase α3 sodium pump
resolves10.1016/0165-0327(94)00102-F
The upregulation of Na+,K+-ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate
resolves10.1002/(SICI)1520-6394(1997)5:2<53::AID-DA1>3.0.CO;2-6
Meta-analysis of erythrocyte Na,K-ATPase activity in bipolar illness
resolves10.1007/BF01250673
Erythrocyte membrane sodium ? potassium adenosine triphosphatase activity in affective disorders
resolves10.1001/archpsyc.1983.01790080103013
RBC Membrane Adenosine Triphosphatase Activities in Patients With Major Affective Disorders
resolves10.1016/j.pnpbp.2011.12.006
Effects of lithium therapy on Na+–K+-ATPase activity and lipid peroxidation in bipolar disorder
resolves10.1111/j.1471-4159.1979.tb05179.x
EFFECTS OF LITHIUM TREATMENT <i>IN VITRO</i> AND <i>IN VIVO</i> ON ACETYLCHOLINE METABOLISM IN RAT BRAIN
resolves10.1073/pnas.0307921101
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade
resolves10.1073/pnas.95.5.2642
Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting
<i>N</i>
-methyl-
<scp>d</scp>
-aspartate receptor-mediated calcium influx
resolves10.1111/j.1471-4159.1993.tb03600.x
Cerebral Cortex G<sub>s</sub>α Protein Levels and Forskolin‐Stimulated Cyclic AMP Formation Are Increased in Bipolar Affective Disorder
resolves10.1016/0014-2999(89)90796-6
Effects of lithium ex vivo on the GTP-mediated inhibition of calcium-stimulated adenylate cyclase activity in rat brain
resolves10.1016/0006-3223(89)90040-1
Effects of GTP on hormone-stimulated adenylate cyclase activity in cerebral cortex, striatum, and hippocampus from rats treated chronically with lithium
resolves10.1111/j.1600-0773.1987.tb01745.x
Mode of Action of Lithium on the Catalytic Unit of Adenylate Cyclase from Rat Brain
resolves10.1046/j.1471-4159.1996.66062402.x
The Phosphoinositide Signal Transduction System Is Impaired in Bipolar Affective Disorder Brain
resolves10.1034/j.1399-5618.2000.020203.x
The high affinity inositol transport system – implications for the pathophysiology and treatment of bipolar disorder
resolves10.1016/S0893-133X(98)00017-7
Behavioral Reversal of Lithium Effects by Four Inositol Isomers Correlates Perfectly with Biochemical Effects on the PI Cycle: Depletion by Chronic Lithium of Brain Inositol Is Specific to Hypothalamus, and Inositol Levels May be Abnormal in Postmortem Brain from Bipolar Patients
resolves10.1016/S0893-133X(99)00037-8
Inhibition of the High Affinity Myo-Inositol Transport System A Common Mechanism of Action of Antibipolar Drugs?
resolves10.1176/ajp.156.12.1902
Temporal Dissociation Between Lithium-Induced Changes in Frontal Lobe <i>myo</i>-Inositol and Clinical Response in Manic-Depressive Illness
resolves10.1007/BF02244552
Therapeutic concentrations of lithium and carbamazepine inhibit cGMP accumulation in human lymphocytes
resolves10.1016/0006-2952(90)90048-P
Lithium but not cholinergic ligands influence guanylate cyclase activity in intact human lymphocytes
resolves10.1016/j.tips.2011.03.006
The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium
resolves10.1007/BF00967326
Evidence that lithium induces a glutamatergic: Nitric oxide-mediated response in rat brain
resolves10.1038/sj.npp.1301640
Chronic Lithium Salt Treatment Reduces CRE/CREB-Directed Gene Transcription and Reverses Its Upregulation by Chronic Psychosocial Stress in Transgenic Reporter Gene Mice
resolves10.1016/j.cnr.2004.09.012
Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status
resolves10.1176/ajp.154.7.976
High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder
resolves10.1017/S1461145709000261
Differential modulation of intracellular Ca2+ responses in B lymphoblasts by mood stabilizers
resolves10.1016/S0165-6147(03)00206-2
Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes
resolves10.1007/s00018-013-1378-1
Wnt and lithium: a common destiny in the therapy of nervous system pathologies?
resolves10.1073/pnas.1300886110
Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis
resolves10.1046/j.1471-4159.2001.00495.x
CREB DNA binding activity is inhibited by glycogen synthase kinase‐3β and facilitated by lithium
resolves10.1503/jpn.110011
A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health
resolves10.1021/ar030197a
Is Competition between Li<sup>+</sup>and Mg<sup>2+</sup>the Underlying Theme in the Proposed Mechanisms for the Pharmacological Action of Lithium Salts in Bipolar Disorder?
resolves10.1034/j.1399-5618.2000.020308.x
Li<sup>+</sup>/Mg<sup>2+</sup> competition at therapeutic intracellular Li<sup>+</sup> levels in human neuroblastoma SH‐SY5Y cells
resolves10.1111/j.1399-5618.2012.01013.x
Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment
resolves10.1016/S0006-3223(00)00252-3
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects?
resolves10.1503/jpn.110097
Large positive effect of lithium on prefrontal cortex <i>N</i>-acetylaspartate in patients with bipolar disorder: 2-centre study
resolves10.1074/jbc.274.10.6039
Long Term Lithium Treatment Suppresses p53 and Bax Expression but Increases Bcl-2 Expression
resolves10.1038/tp.2013.37
Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres
resolves10.1111/j.1399-5618.2009.00729.x
Lithium‐induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue
resolves10.1073/pnas.0400208101
Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment
resolves10.1055/s-2003-45138
Implications of the Neuroprotective Effects of Lithium for the Treatment of Bipolar and Neurodegenerative Disorders
resolves10.1017/S0033291713001165
Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response
resolves10.1016/S0006-3223(00)00969-0
Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder
resolves10.1016/0278-5846(83)90076-3
Chronic lithium treatment and twenty-four hour rhythm of serum prolactin, growth hormone and melatonin in rats
resolves10.1038/sj.mp.4001824
Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes
resolves10.1016/j.jad.2007.03.003
Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study
resolves10.1192/bjp.178.41.s184
Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders
resolves10.1111/j.1399-5618.2008.00499.x
Long‐term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15‐year register‐based follow‐up
resolves10.1016/S0165-0327(98)00145-1
Lithium prophylaxis of recurrent bipolar affective disorder: Long-term outcome and its psychosocial correlates
resolves10.1176/ajp.155.1.30
Long-Term Outcome of Lithium Prophylaxis in Bipolar Disorder: A 5-Year Prospective Study of 402 Patients at a Lithium Clinic
resolves10.1192/S000712500029243X
The Challenge of Predicting Response to Stabilising Lithium Treatment
resolves10.1111/j.1399-5618.2005.00244.x
Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders
resolves10.1034/j.1399-5618.2003.00026.x
Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine
resolves10.1016/S0006-3223(98)00013-4
Mn blood groups and bipolar disorder: evidence of genotypic association and hardy–weinberg disequilibrium
resolves10.1017/S0033291705004484
Psychosocial and demographic factors associated with response to prophylactic lithium. A systematic review for bipolar disorders
resolves10.1176/ajp.126.7.983
Establishment of Diagnostic Validity in Psychiatric Illness: Its Application to Schizophrenia
resolves10.1016/j.pnpbp.2005.03.021
Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder
resolves10.1177/070674370705200606
A Consecutive Series of Treated Affected Offspring of Parents with Bipolar Disorder: Is Response Associated with the Clinical Profile?
resolves10.1176/appi.ajp.163.2.257
Risk and Resilience Markers in Bipolar Disorder: Brain Responses to Emotional Challenge in Bipolar Patients and Their Healthy Siblings
resolves10.1016/j.neulet.2009.10.003
Interacting genes in lithium prophylaxis: Preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients
resolves10.1177/0748730410362713
Nuclear Receptor
<i>Rev-Erb-</i>
α Circadian Gene Variants and Lithium Carbonate Prophylaxis in Bipolar Affective Disorder
resolves10.1111/j.1601-183X.2011.00725.x
Functional genetic variation in the Rev-Erb<i>α</i>pathway and lithium response in the treatment of bipolar disorder
resolves10.1016/j.neulet.2004.11.022
Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-β −50 T/C SNP
resolves10.1038/sj.tpj.6500006
Serotonin transporter gene associated with lithium prophylaxis in mood disorders
resolves10.1016/j.neulet.2006.05.001
Association study of the INPP1, 5HTT, BDNF, AP-2β and GSK-3β GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder
resolves10.1055/s-2005-871239
Prophylactic Lithium Response and Polymorphism of the Brain-Derived Neurotrophic Factor Gene
resolves10.1038/mp.2013.37
Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility
resolves10.1017/S146114570500533X
Lithium response and [minus sign]116C/G polymorphism of XBP1 in Japanese patients with bipolar disorder
resolves10.1017/S1461145705005523
A possible association between the [minus sign]116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder
resolves10.1097/00041444-199903000-00005
A halotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands
resolves10.1002/(SICI)1096-8628(19991015)88:5<567::AID-AJMG24>3.0.CO;2-8
Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in Quebec points to a locus of major effect on chromosome 12q23-q24
resolves10.1017/S1461145710000714
Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses
resolves10.1056/NEJMoa1212444
Variant
<i>GADL1</i>
and Response to Lithium Therapy in Bipolar I Disorder
resolves10.1038/ng.209
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder
resolves10.1038/ncomms4339
Genome-wide association study reveals two new risk loci for bipolar disorder
resolves10.1111/j.1471-4159.2011.07424.x
The effects of chronic treatment with mood stabilizers on the rat hippocampal post‐synaptic density proteome
resolves10.1097/FPC.0b013e328011b5b2
A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder
resolves10.1016/j.biopsych.2012.10.016
The ANK3 Bipolar Disorder Gene Regulates Psychiatric-Related Behaviors That Are Modulated by Lithium and Stress
resolves10.1586/ern.11.184
Gene-expression studies in understanding the mechanism of action of lithium
resolves10.1007/s10571-013-9907-x
Lithium’s Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study
resolves10.1016/j.cnr.2004.09.005
Transcriptional mechanisms of lithium action: therapeutic implications
resolves10.1176/appi.ajp.2009.08111633
A Genomewide Association Study of Response to Lithium for Prevention of Recurrence in Bipolar Disorder
resolves10.2217/pgs.11.102
Evidence for Association of an
<i>ACCN1</i>
Gene Variant with Response to Lithium Treatment in Sardinian Patients with Bipolar Disorder
The 8 references without a DOI — listed, not checked
no DOI — not checkedSchioldann J . History of the Introduction of Lithium into Medicine and Psychiatry. Adelaide, SA, Australia: Adelaide Academic Press, 2009.
no DOI — not checkedJope RS, Jenden DJ, Ehrlich BE, Diamond JM . Choline accumulates in erythrocytes during lithium therapy. N Engl J Med 1978; 299: 833–834.
no DOI — not checkedMaj M . Clinical prediction of response to lithium prophylaxis in bipolar patients: a critical update. Lithium 1992; 3: 15–21.
no DOI — not checkedRybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J . Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005; 57: 124–127.
no DOI — not checkedIkeda M, Kondo K, Iwata N . Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med 2014; 370: 1856–1857.
no DOI — not checkedConsortium on Lithium Genetics, Hou L, Heilbronner U, Rietschel M, Kato T, Kuo PH, et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med 2014; 370: 1857–1859.
no DOI — not checkedSchulze T . Genomic and phenomic correlates of lithium response in bipolar disorder: a consortium on lithium genetics (ConLiGen) report. Bipolar Disord 2014; 16: 26 (abstract).
no DOI — not checkedBergen S, Song J, Lichtenstein P, Landen M . Genome-wide association study of lithium response in a Swedish population. Bipolar Disord 2014; 16: 64 (abstract).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1038/mp.2015.4"><img src="https://citestamp.com/citestamped/10.1038/mp.2015.4/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1038/mp.2015.4)